By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Diosynth Biotechnology (Morrisville) 

Executive Offices
101 J. Morris Commons Lane
Morrisville  North Carolina  27560  U.S.A.
Phone: 919-337-4477 or 866-762-6259
Fax: 919-337-0899


SEARCH JOBS
You Think It Up…We’ll Work It Out

Diosynth Biotechnology has a proven record in clinical & commercial cGMP contract manufacturing of complex recombinant proteins, vaccines, antibody derivatives, enzymes and fusion proteins.

We ensure our customers’ success by rapidly and cost effectively developing scalable, robust processes, applying our expertise with complex molecules, using a broad range of expression systems (Escherichia. coli, Pichia pastoris, Pfenex Expression Technology™, Saccharomyces, CHO, NS0, SP2/0, baculovirus (BEVS), etc.). Our global regulatory experience (FDA [CBER & CDER], EMEA, Health Canada; certified by JMHLW) with 80 different processes will assist you in determining what is relevant for your stage of product development.

Whether your product is in early stage development or you are preparing for BLA/MAA filing, Diosynth Biotechnology is committed to exceeding your expectations.

Diosynth Biotechnology is a part of Schering Plough Corporation.


Key Statistics


Email: info@sp.diosynth.com
Ownership: Private

Web Site: Diosynth Biotechnology (Morrisville)
Employees: ~3,000
Symbol: 
 



Industry
Biotechnology

Segment
Pharmaceuticals





Company News
Selexis SA Announces License Renewal with Diosynth Biotechnology 8/2/2007 9:07:48 AM
Viron Therapeutics Inc. Signs Agreement With Diosynth Biotechnology For Clinical Manufacturing Of VT-111 10/25/2006 10:34:38 AM
Viron Therapeutics Inc. Signs Agreement With Diosynth Biotechnology For Clinical Manufacturing Of VT-111 10/24/2006 11:18:04 AM
Diosynth Biotechnology (Research Triangle Park) Announces Agreement With ImmunoGen, Inc. (IMGN)10/19/2005 5:13:18 PM
Pharming Group (PHGUF.PK) And Diosynth Biotechnology Sign Manufacturing Agreement For Rec. Human C1 Inhibitor10/19/2005 5:12:39 PM
BioSpace Releases Its 3rd Edition Of Bio NC™ 10/19/2005 5:12:33 PM
Vernalis PLC (VNLS) Signs Agreement With Diosynth Biotechnology (Research Triangle Park) For Phase III Manufacture Of V1015310/19/2005 5:12:29 PM
Diosynth Biotechnology (Research Triangle Park) Announces Amendment To Validation And Manufacturing Agreement With NeoPharm (NEOL) For IL13-PE38QQR10/19/2005 5:12:28 PM
Dendreon Corporation (DNDN) Achieves Commercial Scale Of Antigen For Provenge 10/19/2005 5:12:03 PM
Diosynth Biotechnology (Research Triangle Park) Is Selected By NeoPharm (NEOL) to Produce IL13-PE38QQR For An Important Phase III Trial10/19/2005 5:10:44 PM
12
//-->